Search clinical trials for: BMS 587101

Total 3152 results

Bristol-Myers Squibb

Completed

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Bristol-Myers Squibb

Completed

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan

Neoplasms

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Neuroendocrine Tumors | Carcinoid Tumor

United States
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Bristol-Myers Squibb

Completed

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Systemic Lupus Erythematosus | Inflammatory Bowel Diseases | Psoriasis | Arthritic Psoriasis

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Completed

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Cancer

United States, France
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Allyx Therapeutics
Michael J. Fox Foundation for Parkinson's Research

Recruiting

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

Parkinson Disease

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

United States, Australia, Canada, France, Germany, Ireland, Italy, Spain, United Kingdom
Bristol-Myers Squibb

Terminated

Multiple Ascending Dose of BMS-911543

Cancer

United States, Australia
Bristol-Myers Squibb

Completed

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Thrombosis

United States
Bristol-Myers Squibb
This trial was conducted previously by Cormorant

Completed

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Solid Tumor

United States
InspireMD

Terminated

MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction (MASTER-II)

ST Elevation Myocardial Infarction

United States, Poland, France, Spain, United Kingdom, Finland, Netherlands, Israel, Czech Republic, Germany, Belgium, Estonia
Academisch Medisch Centrum - Universiteit van Amsterdam...

Not yet recruiting

Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success? (OUTBACK)

Osteochondral Lesion of Talus
Bristol-Myers Squibb

Completed

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

Atherosclerosis

United States
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Advanced Cancer

United States, Spain, France, Austria, Italy, Australia, Canada, Switzerland
Bluedrop Medical Limited

Recruiting

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration (MASTER)

Diabetic Foot

United States
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Taiwan, Japan, Brazil, Colombia, Germany, Poland, Puerto Rico, China, Mexico, Argentina, France, Chile, Australia, India, Spain, United Kingdom, Romania, Ireland
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
R-Pharm

Completed

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of, Taiwan, Japan, Singapore, Hong Kong
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Terminated

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Canada, Denmark, France, Finland
Bristol-Myers Squibb

Terminated

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Non Small Cell Lung Cancer

United States
Bayer

Completed

Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers

Alzheimer's Disease | Positron-Emission Tomography

Netherlands, Sweden
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Alzheimer's Disease
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants

Healthy

China
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
R-Pharm

Completed

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

Solid Tumors
Bristol-Myers Squibb

Completed

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Soft Tissue Sarcoma | Transitional Cell Carcinoma | Advanced Non-small Cell Lung Cancer | Gastric/Esophageal Adenocarcinoma | Pancreatic Cancer Including Ampulla of Vater

United States, Argentina, Germany, Belgium, Canada, Poland, Netherlands, United Kingdom, France
Bristol-Myers Squibb

Completed

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Neoplasms | Solid Tumors | Metastases

Australia
Bristol-Myers Squibb

Completed

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Cancer

Japan
Bristol-Myers Squibb

Withdrawn

Japanese Phase 1 Study of BMS-844203 (CT322)

Neoplasms

Japan
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Prostate Cancer

Japan
London School of Hygiene and Tropical Medicine
Camden Primary Care Trust, London; London Borough of Camden Housing and Adult...

Completed

Health and Environmental Effects of Boiler Management Systems in Social Housing

Hot Water Burns (Scalds)

United Kingdom
Bristol-Myers Squibb

Completed

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Neoplasm Metastasis | Tumors

Italy, United Kingdom, United States, Canada
Bristol-Myers Squibb

Completed

A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants

Healthy Volunteers

United Kingdom
Yale University
National Cancer Institute (NCI)

Terminated

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

Cancer Head Neck | Metastatic Cancer | Metastatic Lung Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

France, United States, Spain, Australia, Italy, Switzerland, United Kingdom
Bristol-Myers Squibb

Completed

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Healthy | Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Healthy Participants

United States
Dr. August Wolff GmbH & Co. KG Arzneimittel
SIT Skin Investigation and Technology Hamburg GmbH

Completed

In-Use Test of a Cosmetic Product in Subjects With Chronically Itchy Scalp

Pruritus of the Scalp

Germany
Bristol-Myers Squibb

Completed

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

Healthy Subjects and Atopic Dermatitis Subjects

United Kingdom

Search clinical trials for: BMS 587101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations